On March 31st, Jafron Biomedical Co., Ltd. (SZ 300529), the world’s leading provider of hemoadsorption products and therapies, released its 2022 annual report. In 2022, Jafron remained focused on its main business and achieved an operating revenue of $361million, a year-on-year decrease of 6.88%, generating a net profit of $129 million which reflects a 25% drop versus 2021.

In terms of specific business performance, although the profit of kidney and liver-related businesses decreased significantly compared to the previous year, the DX-10 blood purification machine, the "knockout product" which can support various treatment modes such as CRRT and artificial liver, achieved a sales income of $27 million, a year-on-year increase of 181.79%. Jafron has achieved leapfrog development in 2022 with the application of hemoadsorption technology in cardiopulmonary bypass, sepsis, acute pancreatitis, and other severe diseases. Consumables related to critical diseases (HA330, HA380, and CA series) have entered more than 1,700 hospitals and achieved an income of $33.26 million in the Chinese market, with a year-on-year growth of 32.47%. Jafron continues to improve its overall research and development strength and invested about $36.89 million in R&D in 2022, with an escalation of 115.17%. Up to the end of 2022, 306 patents were authorized in total.

During the reporting period, Jafron achieved operational multi-targets to support its global development: (1) New academic collaboration with more than 50 international experts and more than 10 international clinical studies initiated; (2) Formation of local commercial team in more than 10 countries; (3) Collaboration with B. Braun and Nikkiso on the biocompatibility with HA380 on OMNI and Aquarius CRRT platforms, (4) In the medical affairs, Jafron's original-developed technology DPMAS was accepted into the Expert Consensus published in Hepatology International (IF: 9.029), and more than 30 international research papers were published in top academic journals, in particular, Randomized Control Study on Hemoperfusion Combined with Hemodialysis versus Standard Hemodialysis: <Effects on Middle-Molecular-Weight Toxins and Uremic Pruritus> and Expert Consensus <Hemoperfusion in Maintenance Hemodialysis Patients> were officially published. 

As of the publication date of the annual report, Jafron’s hemoadsorption cartridges and therapies have been successfully applied in 86 countries, implementing the treatment for kidney disease, poisoning, liver disease, critical illness, and immune disease. In the near future, Jafron will continue to devote itself to Dual-core Business Strategy with a focus on the fields of chronic and acute therapies with hemoadsorption, and will commit to the product strategy of “improving quality and efficiency", aiming to provide more creative and efficacious devices to the patients around the globe. To reach the goal of international development, Jafron is committed to social responsibilities in communities and healthcare systems, and to pioneer the advancment of hemoadsorption.